244 related articles for article (PubMed ID: 17470677)
1. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia.
Lappin TR; Maxwell AP; Johnston PG
Oncologist; 2007 Apr; 12(4):362-5. PubMed ID: 17470677
[No Abstract] [Full Text] [Related]
2. Erythropoietin: high profile, high scrutiny.
Crawford J
J Clin Oncol; 2007 Mar; 25(9):1021-3. PubMed ID: 17312331
[No Abstract] [Full Text] [Related]
3. Response to "effect of patient exclusion criteria on the efficacy of erythropoiesis-stimulating agents in patients with cancer-related anemia".
Coiffier B
Oncologist; 2005 Oct; 10(9):762-3; author reply 764-5. PubMed ID: 16249359
[No Abstract] [Full Text] [Related]
4. Weighing the hazards of erythropoiesis stimulation in patients with cancer.
Khuri FR
N Engl J Med; 2007 Jun; 356(24):2445-8. PubMed ID: 17568023
[No Abstract] [Full Text] [Related]
5. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.
Steensma DP
J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668
[No Abstract] [Full Text] [Related]
6. Erythropoiesis-stimulating agents--time for a reevaluation.
Unger EF; Thompson AM; Blank MJ; Temple R
N Engl J Med; 2010 Jan; 362(3):189-92. PubMed ID: 20054037
[No Abstract] [Full Text] [Related]
7. Erythropoietin, the FDA, and oncology.
Steinbrook R
N Engl J Med; 2007 Jun; 356(24):2448-51. PubMed ID: 17568025
[No Abstract] [Full Text] [Related]
8. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia.
Bohlius J; Engert A; Schwarzer G
JAMA; 2008 Dec; 300(24):2854-5; author reply 2855-7. PubMed ID: 19109112
[No Abstract] [Full Text] [Related]
9. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia.
Kara O; Dizdar O; Altundag K
JAMA; 2008 Dec; 300(24):2855; author reply 2855-7. PubMed ID: 19109113
[No Abstract] [Full Text] [Related]
10. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
Singh AK
J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
[No Abstract] [Full Text] [Related]
11. Response to "Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia".
Littlewood TJ
Oncologist; 2007 Aug; 12(8):1031-2; author reply 1032-4. PubMed ID: 17766663
[No Abstract] [Full Text] [Related]
12. Amgen's point of view on epoetins.
Seidenberg B; Perlmutter RM
Lancet Oncol; 2004 Apr; 5(4):206-7. PubMed ID: 15050950
[No Abstract] [Full Text] [Related]
13. Cancer- and treatment-related anemia.
Rodgers GM; Cella D; Chanan-Khan A; Chesney C; Cleeland C; Coccia PF; Demetri GD; Djulbegovic B; Garst JL; Gore M; Kraut EH; Lin WC; Millenson M; Mock V; Reinke D; Rosenthal J; Sabbatini P
J Natl Compr Canc Netw; 2005 Nov; 3(6):772-89. PubMed ID: 16316613
[No Abstract] [Full Text] [Related]
14. Erythropoietin: the swinging pendulum.
Oster HS; Neumann D; Hoffman M; Mittelman M
Leuk Res; 2012 Aug; 36(8):939-44. PubMed ID: 22579365
[TBL] [Abstract][Full Text] [Related]
15. Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA).
Goldsmith D; Covic A
Nephrol Dial Transplant; 2010 Jun; 25(6):1734-7. PubMed ID: 20200007
[No Abstract] [Full Text] [Related]
16. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
[TBL] [Abstract][Full Text] [Related]
17. FDA panel scrutinizes safety of anti-anemia drugs.
Randal J
J Natl Cancer Inst; 2004 Jul; 96(14):1061. PubMed ID: 15265966
[No Abstract] [Full Text] [Related]
18. Erythropoietin in cancer patients.
Glaspy JA
Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
[TBL] [Abstract][Full Text] [Related]
19. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR; Dunst J; Vaupel P
Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
[TBL] [Abstract][Full Text] [Related]
20. New limits advised for anemia drugs.
Mitka M
JAMA; 2007 Jun; 297(22):2464. PubMed ID: 17565074
[No Abstract] [Full Text] [Related]
[Next] [New Search]
